FDA approves Jascayd (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade – Boehringer Ingelheim
Jascayd (nerandomilast) tablets has been approved by the FDA as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients. Jascayd is the first and only… read more.

